This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2021
ESMO 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ESMO 2021 Bladder Cancer
Viewing 1-20 of 27 articles
ESMO 2021: High- vs Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer (NABUCCO Cohort 2)
ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)
ESMO 2021: Cisplatin (Cis)-Related Immunomodulation and Efficacy with Atezolizumab + Cis- vs Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer (mUC)
ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer: AURA Trial
ESMO 2021: Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer
ESMO 2021: High- Versus Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer: NABUCCO Cohort 2
ESMO 2021: A Discussion on the Results of the GETUG/AFU VESPER V05 Phase III Trial and on Pembrolizumab in Combination with sEphB4-HSA (B4) in a Phase II Trial for Previously Treated Metastatic Urothelial Carcinoma
ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC)
ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC
ESMO 2021: IMvigor011: A Global, Double-Blind, Randomized Phase 3 Study of Atezolizumab Versus Placebo As Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Post Cystectomy
ESMO 2021: The Phase 2 NORSE Trial Discussion: A Novel Combination in the First-Line Setting for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and FGFR Alterations
ESMO 2021: Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase 2 Results From the NORSE Study
ESMO 2021: Tissue and Blood-Based Biomarkers for Urothelial Cancer
ESMO 2021: Results of the GETUG/AFU VESPER V05 Phase III Trial (ddMVAC vs GC in MIBC) and the Phase II Trial of Pembrolizumab plus sEphB4-HSA in Metastatic Urothelial Carcinoma
ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC)
ESMO 2021: Erdafitinib or Erdafitinib Plus Cetrelimab for Patients with Metastatic or Locally Advanced Urothelial Carcinoma and Fibroblast Growth Factor Receptor Alterations: First Phase 2 Results From the NORSE Study
ESMO 2021: The Phase 2 NORSE Trial Discussion: Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and FGFR Alterations
ESMO 2021: Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with MIBC: GETUG/AFU VESPER V05 Phase III Trial
ESMO 2021: Novel Treatment Strategies in Advanced Urothelial Cancer
ESMO 2021: KEYNOTE-676 Cohort B: Randomized Comparator-Controlled Cohort To Evaluate Efficacy and Safety of Pembrolizumab Plus BCG in Patients With High-Risk BCG Treatment-Naive NMIBC
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free